Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 22 cents a share - Earnings Preview

Reviva Pharmaceuticals Holdings

10/03/2023 11:39

* Reviva Pharmaceuticals Holdings, Inc.  RVPH.OQ 
 RVPH.O  is
expected to show no change in quarterly revenue when it reports 
results on March 13 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Reviva
Pharmaceuticals
Holdings, Inc. is for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reviva
Pharmaceuticals Holdings, Inc. is $13​, above​ its last closing
price of $4.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.28       -0.29      -0.18     Beat    37.2
 Jun. 30 2022  -0.36       -0.35      -0.29     Beat    17.1
 Mar. 31 2022  -0.28       -0.28      -0.40     Missed  -42.9​
 Dec. 31 2021  -0.25       -0.25      -0.22     Beat    12
 ​​Sep.        -0.24       -0.23      -0.12     Beat    48.9
 30 2021                                                
 Jun. 30 2021  -0.24       -0.24      -0.12     Beat    50​
                                      -0.10             
 Dec. 31 2020              -0.06                        
 This summary was machine generated March 10 at 11:39 GMT.  All
figures in US dollars  unless otherwise stated